ARISTOSPAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aristospan, and what generic alternatives are available?
Aristospan is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in ARISTOSPAN is triamcinolone hexacetonide. There are fifty-one drug master file entries for this compound. Additional details are available on the triamcinolone hexacetonide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ARISTOSPAN?
- What are the global sales for ARISTOSPAN?
- What is Average Wholesale Price for ARISTOSPAN?
Summary for ARISTOSPAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 37 |
Clinical Trials: | 1 |
Patent Applications: | 3,804 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ARISTOSPAN at DailyMed |
![ARISTOSPAN drug patent expirations Drug patent expirations by year for ARISTOSPAN](/p/graph/s/t/ARISTOSPAN-patent-expirations.png)
Recent Clinical Trials for ARISTOSPAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Florida | Phase 2 |
US Patents and Regulatory Information for ARISTOSPAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | ARISTOSPAN | triamcinolone hexacetonide | INJECTABLE;INJECTION | 016466-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sandoz | ARISTOSPAN | triamcinolone hexacetonide | INJECTABLE;INJECTION | 016466-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |